The treatment of Alzheimer's disease (AD) is up to today one of the most unsuccessful
examples of biomedical science. Despite the high number of literature evidences detailing …

Innovative breakthroughs in nanotechnology are having a substantial impact in healthcare,
especially for brain diseases where effective therapeutic delivery systems are desperately …

Alzheimer's disease, Parkinson's disease and stroke are the most common CNS diseases,
all characterized by progressive cellular dysfunction and death in specific areas of the …

The blood-brain barrier (BBB), the unusual microvascular endothelial interface between the
central nervous system (CNS) and the circulatory system, is a major hindrance to drug …

The number of people diagnosed with Alzheimer's disease (AD) is increasing steadily as the
world population ages, thus creating a huge socio-economic burden. Current treatments …

The blood–brain barrier poses major hurdles in the treatment of brain-related ailments. Over
the past decade, interest in peptides-based therapeutics has thrived a lot because of their …

In this article, we describe how nanoparticles work in photothermally triggered drug delivery,
starting with a description of the plasmon resonance and the photothermal effect, and how …

The blood-brain barrier (BBB), a selective barrier regulating the active and passive transport
of solutes in the extracellular fluid of the central nervous system, prevents the delivery of …

The blood-brain barrier accounts for the high attrition rate of the treatments of most brain
disorders, which therefore remain one of the greatest health-care challenges of the twenty …

Highlights•Targeting of the BBB is a great opportunity for brain delivery of therapeutics.•BBB
peptide shuttles can target both passive and active transport mechanisms present at the …